Clinical Trial Update: Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors [Phase 4]

View source ↗

Summary

A Phase 4 double-blind randomized trial comparing suvorexant 20 mg to placebo for the treatment of insomnia in cancer survivors was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Insomnia

Drugs mentioned

• Suvorexant (suvorexant)

Snippet

Sponsor: Medical University of South Carolina | Conditions: Breast Cancer, Insomnia | Phase 4 | Status: TERMINATED